María Jesús Rubio-Pérez

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Antonio González-Martı́n, Bhavana Pothuri, Ignace Vergote et al. · New England Journal of Medicine · 2019 · 2.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial

Éric Pujade-Lauraine, Frédèric Selle, Giovanni Scambia et al. · Annals of Oncology · 2023 · 107 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial

Antonio González-Martı́n, Christophe Desauw, Florian Heitz et al. · European Journal of Cancer · 2022 · 72 citations · Full text

Medicine, Oncology, Pharmacology +16

LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial

Éric Pujade-Lauraine, Frédèric Selle, Giovanni Scambia et al. · Annals of Oncology · 2021 · 56 citations

Medicine, Gynecology, Oncology +15

Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.

Philipp Harter, Fabian Trillsch, Aikou Okamoto et al. · Journal of Clinical Oncology · 2023 · 54 citations

Medicine, Oncology, Pharmacology +17